> top > docs > PMC:4014359 > divs

PMC:4014359 JSONTXT

Divisions (9) JSON TSV

div. section text # proj. length # Ann.
0 TIAB Efficacy and tolerability of agomelatine in the treatment of depression Depression is a severe and u 3 974 39 show
1 Introduction Depression is the most prevalent mental disorder in the world with a 3.9%–4% 12-month prevalence in 2 719 22 show
2 Method For this article, literature was identified through a computerized search of MEDLINE via PubMed for 2 766 37 show
3 Treatment of depression There are many different therapeutic approaches to depression.4,5 Treatment in the acute phase of ma 2 2413 84 show
4 Circadian rhythms and depression Circadian rhythms (CR) include all physiological processes (biological and behavioral) that display 2 5942 124 show
5 Agomelatine – pharmacology Agomelatine is a new antidepressant with a novel mechanism of action. It exhibits antidepressant and 2 2850 7 show
6 Efficacy Agomelatine (25–50 mg) proved its antidepressant efficacy in three pivotal, 6–8 week, randomized, pl 2 13373 235 show
7 Safety In placebo-controlled clinical trials, the safety profile of agomelatine, including the incidence of 2 5807 104 show
8 Conclusion Effective treatment of depressive disorder is complex and important from both the personal and popul 2 1723 36 show